# Judge — L4-TICK9-COMPARE, iteration 1

**Judge:** Agent J (Kimi K3). Did not write this increment. Mood: critic.
**Date of review:** 2026-09-02.
**Files reviewed (read in full):**
- `src/content/comparisons/cagrisema-vs-tirzepatide.mdx`
- `src/content/blog/cagrilintide-redefine-1-amylin-validated.mdx`

**Independent re-fetches this run (not the implementer's):**
- `efetch` PMID 40544433 (REDEFINE 1, NEJM 2025) — full abstract retrieved.
- `efetch` PMID 35658024 (SURMOUNT-1, NEJM 2022) — full abstract retrieved.
- CT.gov API v2 `NCT06131437` — full record retrieved.
- Cross-check: PowerShell `Select-String` on both files for `22-23`, `22.7`, `22.9`, `approximately 22`, `63%`, `28.7`, `TRIUMPH` → **zero matches**. Positive control (`CagriSema`, 31 matches) confirms the negative is real. (Cursor Grep tool returned false negatives this session, incl. for known-present strings; PowerShell is the cited evidence.)
- `git diff --stat HEAD -- src/content/` → modifications only, no new files.

---

## Per-criterion verdicts

| # | Criterion | Verdict | Evidence |
|---|---|---|---|
| 1 | "approximately 22-23%" stripped; table labels REDEFINE 1 −20.4% (68 wk, treatment-policy) vs SURMOUNT-1 −20.9% (15 mg, 72 wk, treatment-regimen) | **PASS** | Select-String: no `22-23` / `approximately 22` in either file. Comparison REDEFINE table, Efficacy table, Summary table, and Key Takeaway 1 all carry the labeled figures. PMID 40544433 abstract: "−20.4% with cagrilintide-semaglutide as compared with −3.0% with placebo (estimated difference, −17.3 percentage points; 95% CI, −18.1 to −16.6)", "assessed with the treatment-policy estimand", 68 weeks. PMID 35658024 abstract: "−20.9% (95% CI, −21.8 to −19.9) with 15-mg doses and −3.1% … with placebo", "The treatment-regimen estimand assessed effects regardless of treatment discontinuation", 72 weeks. Both labels match the papers exactly. |
| 2 | 22.7% stripped from amylin blog; −20.4% vs −3.0% kept from PMID 40544433 | **PASS** | Select-String: no `22.7` in the blog. Blog quotes "20.4% mean weight loss versus 3.0% with placebo (estimated difference −17.3 percentage points; 95% CI −18.1 to −16.6)" — exact abstract match. Blog's statement "The PubMed abstract fetched 2026-09-02 does not report a trial-product percent; this page does not quote one" is **true** — the fetched abstract reports only the treatment-policy estimand. Window-dated absence, per L4 bar. |
| 3 | NCT06131437 design-only; hasResults false; no head-to-head percent | **PASS** | CT.gov live record: `overallStatus: COMPLETED`, `hasResults: false`, enrollment 809 ACTUAL, masking NONE (open-label), RANDOMIZED/PARALLEL, arms "up to 84 weeks", primary outcome timeframe "baseline (week 0) to end of treatment (week 84)". Comparison Key Takeaway 5 states exactly this ("84-week open-label randomised trial (actual enrollment 809; COMPLETED; CT.gov hasResults false as of 2026-09-02), so this page does not quote a percent") and quotes no percent. Dated absence. |
| 4 | ~$1,000/month NOT stripped (declared out of increment) | **PASS (as scoped)** | Pricing row still reads "~$1,000/month". Implementer disclosed this in the note and tied it to TICK6-PRICE rather than silently fixing or silently keeping. Not a fail criterion for this loop; recorded as residual below. |
| 5 | No new URLs | **PASS** | `git diff --stat HEAD -- src/content/`: 102 modified files, zero additions. Both claimed files are pre-existing slugs. |
| 6 | OSA 63% / TRIUMPH 28.7% not restored | **PASS** | Select-String: no `63%`, `28.7`, or `TRIUMPH` in either file. The comparison FAQ mentions Zepbound's OSA *indication* (FDA-label fact), not the 63% efficacy figure — not a violation. |

**L4 standing fail-criteria screen (LOOPS.md):** no resolution-only topical proof offered (I topically matched both abstracts myself: correct papers, correct drugs, correct trials — no REDEFINE-1/-2 sibling mixup: 40544433 is REDEFINE 1 / NCT05567796); no efficacy estimand headlined (22.7% gone, treatment-policy leads); no undated absence claims; no fuzzy auto-attach; no new identifiers introduced.

## Gaming check

The increment is honestly scoped, which is the opposite of the usual gaming pattern. The implementer (a) replaced the stripped sponsor-efficacy figure with the papers' own treatment-policy/regimen numbers rather than a fresh unsourced one; (b) added estimand labels and an explanatory note where a silent swap would have looked cleaner in review; (c) explicitly listed what was NOT done (price strip, unsourced GI table, OAuth) instead of claiming a broader win; (d) labeled the note "not a KEEP" rather than self-passing. The one place a quieter edit could have hidden — the blog's "abstract does not report a trial-product percent" sentence — I verified against the live abstract and it is accurate. No overturned SEO claims used, no URL growth, no self-marking.

## Residual (not this increment's fails; for future loops)

- `~$1,000/month` pricing row — deferred to TICK6-PRICE by design.
- GI side-effect range table (~40–45% nausea etc.) and `≥20%/~55%`, `≥25%/~35–36%` rows on the comparison are hedged but not tied to fetched figures this run; REDEFINE 2's −13.7% (PMID 40544432) not re-fetched by me — outside the required re-fetch set.
- HbA1c −2.3% row (tirzepatide) unsourced on the page.

## Verdict

**KEEP.** All five claimed outcomes verified against independently re-fetched sources; zero fail criteria triggered; no gaming detected.
